Periodic Reporting for period 2 - V-LAP (A revolutionary direct, daily heart monitoring platform for long-term tailored treatment of Heart Disease patients.)
Período documentado: 2019-04-01 hasta 2020-03-31
Using cutting-edge technology, the V-LAP monitors the pressure in the heart's left atrium (LAP). This allows physicians to make informed decisions and to provide their patients with better treatment based on real-time clinical data and powerful AI algorithms. Vectorious' V-LAP empowers physicians by providing them with a practical solution for direct daily measurement of left atrial pressure. The real-time tracking method introduces remote heart failure care, whereby physicians can provide specific instructions, modify dosing regimens and make better decisions based on artificial intelligence (AI).
The V-LAP monitors the patient’s in-heart pressure on a daily basis. Daily monitoring with the Vectorious V-LAP takes only one minute, enabling physicians to curb heart failure progress by adjusting a medication regimen more precisely. Monitoring can take place anywhere, enabling the patient to maintain a normal life.
The V-LAP creates better clinical outcomes by achieving early detection, higher engagement, holistic monitoring and harnessing AI. The system offers the highest standard of treatment for patients through optimal treatment, self-management of the disease, quick procedure, and 24/7 remote monitoring.
William T Abraham (Ohio State University, Columbus, USA) commented: “The increase of left atrial pressure is the most specific and earliest sign of impending heart failure exacerbation—long before clinical symptoms occur. V-LAP’s unmet clinical need has been evident for years, and the cardiology profession will benefit greatly from the availability of technology that can provide this valuable indication non-invasively on a daily basis.”
Horst Sievert (CardioVascular Center Frankfurt, Germany), who performed the first implantation, stated: “This technology will really change the way we manage patients with severe heart failure. This is the first device that specifically enables us to monitor pressure within the left side of the heart – and because of its cloud-based system, we can access patient data on-demand, monitoring the atrial pressure and managing dosages, medications and overall quality of life consistently and remotely.”
This project has enabled Vectorious to advance through the clinical trial and gain evidence for the CE marking and launch the V-LAP technology into the market. This project marks a major stepping stone in the development of the company, and for the development of the Heart Failure treatment market as a whole.